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Low dose chloroquine decreases insulin 
resistance in human metabolic syndrome 
but does not reduce carotid intima-media 
thickness
Janet B. McGill1*† , Mariko Johnson1†, Stacy Hurst1, William T. Cade2, Kevin E. Yarasheski1, Richard E. Ostlund1, 
Kenneth B. Schechtman3, Babak Razani4, Michael B. Kastan5, Donald A. McClain6, Lisa de las Fuentes4, 
Victor G. Davila‑Roman4, Daniel S. Ory4, Samuel A. Wickline4 and Clay F. Semenkovich1,7*
Abstract 
Background: Metabolic syndrome, an obesity‑related condition associated with insulin resistance and low‑grade 
inflammation, leads to diabetes, cardiovascular diseases, cancer, osteoarthritis, and other disorders. Optimal therapy 
is unknown. The antimalarial drug chloroquine activates the kinase ataxia telangiectasia mutated (ATM), improves 
metabolic syndrome and reduces atherosclerosis in mice. To translate this observation to humans, we conducted two 
clinical trials of chloroquine in people with the metabolic syndrome.
Methods: Eligibility included adults with at least 3 criteria of metabolic syndrome but who did not have diabetes. 
Subjects were studied in the setting of a single academic health center. The specific hypothesis: chloroquine improves 
insulin sensitivity and decreases atherosclerosis. In Trial 1, the intervention was chloroquine dose escalations in 3‑week 
intervals followed by hyperinsulinemic euglycemic clamps. Trial 2 was a parallel design randomized clinical trial, and 
the intervention was chloroquine, 80 mg/day, or placebo for 1 year. The primary outcomes were clamp determined‑
insulin sensitivity for Trial 1, and carotid intima‑media thickness (CIMT) for Trial 2. For Trial 2, subjects were allocated 
based on a randomization sequence using a protocol in blocks of 8. Participants, care givers, and those assessing 
outcomes were blinded to group assignment.
Results: For Trial 1, 25 patients were studied. Chloroquine increased hepatic insulin sensitivity without affecting 
glucose disposal, and improved serum lipids. For Trial 2, 116 patients were randomized, 59 to chloroquine (56 ana‑
lyzed) and 57 to placebo (51 analyzed). Chloroquine had no effect on CIMT or carotid contrast enhancement by MRI, 
a pre‑specified secondary outcome. The pre‑specified secondary outcomes of blood pressure, lipids, and activation of 
JNK (a stress kinase implicated in diabetes and atherosclerosis) were decreased by chloroquine. Adverse events were 
similar between groups.
Conclusions: These findings suggest that low dose chloroquine, which improves the metabolic syndrome through 
ATM‑dependent mechanisms in mice, modestly improves components of the metabolic syndrome in humans but is 
unlikely to be clinically useful in this setting.
Trial registration ClinicalTrials.gov (NCT00455325, NCT00455403), both posted 03 April 2007
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Introduction
A combination of increased triglycerides, low HDL cho-
lesterol, hypertension, above normal fasting glucose, and 
increased waist circumference constitutes the metabolic 
syndrome [1], which predisposes to diabetes, cardiovas-
cular disease, and all-cause mortality [2]. Current therapy 
is directed at individual components of the syndrome, 
which are related to insulin resistance. Obesity-related 
insulin resistance is associated with low-grade systemic 
inflammation characterized by increased activation of a 
stress kinase known to induce insulin resistance, c-Jun 
N-terminal kinase (JNK) [3]. Pronounced weight loss is 
associated with decreased cardiovascular events [4], but 
there are other causes of insulin resistance besides obe-
sity that could provide insight into relationships between 
insulin resistance and cardiovascular disease. DNA dam-
age disorders including Hutchinson–Gilford progeria, 
Werner syndrome, Cockayne syndrome, and ataxia telan-
giectasia are associated with insulin resistance and vas-
cular disease [5]. Mice deficient in ataxia telangiectasia 
mutated (ATM), the kinase mutated in ataxia telangiec-
tasia, have increased activation of JNK in macrophages, 
insulin resistance, hypertension, and increased athero-
sclerosis [6–8]. ATM activation by the anti-malarial drug 
chloroquine decreases macrophage JNK activation, blood 
pressure, insulin resistance, and atherosclerosis in mice 
[6, 9].
Since the ATM axis is associated with altered hepatic 
insulin sensitivity and atherosclerosis in mice, we trans-
lated these rodent data to humans with metabolic syn-
drome in two exploratory clinical trials: (1) A dose 
escalation study with a primary endpoint of insulin sen-
sitivity and pre-specified secondary endpoints including 
serum lipids and blood pressure; and (2) Placebo or chlo-
roquine treatment for 1 year with a primary endpoint of 
carotid intima-media thickness, a noninvasive predictor 
of cardiovascular events [10]. The 1  year study utilized 
the lowest dose associated with improved insulin sensi-
tivity in the dose escalation study and included pre-spec-
ified secondary endpoints such as carotid MRI, activation 




These single center studies were approved by the Wash-
ington University Human Research Protection Office. All 
subjects gave informed consent and were compensated 
for their participation. A data safety and monitoring 
board convened by the National Heart, Lung and Blood 
Institute (NHLBI) supervised the trials.
For both the dose escalation and double blind tri-
als, inclusion criteria included men and women of any 
ethnic group between the ages of 18–60 (Trial 1), and 
18–70 (Trial 2) (the difference in age between protocols 
was intended to make the randomized trial more per-
tinent to a broader age group) who had at least 3 of the 
components of the metabolic syndrome: elevated fast-
ing triglycerides (≥ 1.69  mmol/L); low HDL cholesterol 
(< 1.29 mmol/L in women, < 1.03 mmol/L in men); hyper-
tension (≥ 130/85  mm Hg ≤ 160/100  mmHg) untreated, 
or hypertension controlled (≤ 150/90 mm Hg) on a sta-
ble medication regimen; increased waist circumference 
(> 89  cm in women, > 102  cm in men); elevated fasting 
glucose (≥ 5.6 mmol/L and < 7.0 mmol/L). For a diagno-
sis of hypertension, measurements were repeated on two 
separate days. Fasting glucose was also repeated on two 
separate days. Fasting lipids were performed once before 
enrollment but repeated throughout the interventions.
Exclusion criteria were extensive and included: known 
prior treatment with chloroquine or hydroxychloro-
quine, BMI > 45 kg/m2, coronary artery disease or other 
vascular disease, history of stroke, eGFR (estimated glo-
merular filtration rate) < 60  ml/min/1.73  m2, diabetes, 
seizure disorder, history of psoriasis, hematological dis-
orders (including anemia), current malignancy, asthma 
or COPD (chronic obstructive pulmonary disease), liver 
disease (including transaminases > 2× upper limit of 
normal), active infection (including HIV-human immu-
nodeficiency virus), any serious illness requiring ongo-
ing medical care, major psychiatric illness, lipid lowering 
medications (other than statins and < 1 g daily fish oils), 
severe hypertension at baseline or taking more than 
three antihypertensives, use of cimetidine or vitamin E, 
pregnancy or lactation or intention to become pregnant, 
inadequate use of contraception, glucose-6-phosphate 
dehydrogenase deficiency, auditory disease or hearing 
loss, retinal disease (especially presence of drusen or pig-
mentary changes at the macula), and any ocular disease 
interfering with the ability to rigorously assess the retina.
A CONSORT statement flow diagram for the first trial 
is shown in Fig.  1. The study design for the first trial is 
shown in Fig. 2a. One hundred forty-four subjects were 
screened for participation in Trial 1 and 35 individuals 
with the metabolic syndrome qualified. Twenty-five sub-
jects completed the protocol. Ten discontinued the study 
Keywords: Chloroquine, Metabolic syndrome, Carotid intima‑media thickness, Insulin sensitivity, Glucose disposal, 
Atheroma, Blood pressure, Lipids, JNK
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Fig. 1 CONSORT statement flow diagram for subjects in dose escalation study
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for reasons that included: starting a new medication dur-
ing the protocol [3], new diagnosis of diabetes during 
the protocol [1], difficult IV access [1], worsening joint 
symptoms [1], and miscellaneous issues unrelated to 
the protocol (such as relocation, 4). For this single blind, 
placebo-controlled study, each subject took a capsule that 
was identical in appearance for 21 days. For the first limb, 
capsule contents were inert. For the second limb, three 
of the 21 capsules (administered at weekly intervals) con-
tained 80 mg of chloroquine and the remaining capsules 
were inert. For the third and fourth limbs, capsules con-
tained 80 or 250  mg of chloroquine, respectively. Each 
limb was separated by a washout period to allow recov-
ery from the blood drawing of the clamp procedure. 
It was not possible to randomize limb order due to the 
extremely long half-life of chloroquine; ingestion during 
an early limb would be associated with tissue levels of the 
drug and its metabolites during a later placebo limb.
A CONSORT statement flow diagram for the second 
trial is shown in Fig. 3. The study design for the second 
trial is shown in Fig. 4a. The blind was held by a research 
pharmacist, who provided the randomization sequence 
to the blinded research nurses or physicians who enrolled 
participants and assigned interventions that included 
study medications that were identical in appearance. 
Three hundred fifty-seven subjects were screened for 
participation in Trial 2 and 155 non-diabetic individuals 
with metabolic syndrome qualified at the initial screen-
ing visit. Of these, 21 withdrew consent before the sec-
ond screening visit, 4 withdrew consent after the second 
screening visit and 14 did not qualify for randomization 
due to abnormal eye exams [4], abnormal carotid imag-
ing [2], anemia [3], G6PD deficiency [2], abnormal liver 
function tests [2], and psoriasis [1]. The remaining 116 
subjects were randomized to placebo or chloroquine. 
Of those randomized, 19 assigned to placebo and 20 
assigned to chloroquine were being treated for hyper-
tension, and were taking 1.3 ± 1.1 and 1.1 ± 1.0 antihy-
pertensive medications respectively. 15 subjects in each 
group were taking a statin.
Hyperinsulinemic–euglycemic clamp procedure
At the end of each limb depicted in Fig. 2a, subjects pre-
sented after an overnight fast. The antecubital vein was 
catheterized for infusion of insulin, glucose and tracer 
solutions, a hand vein was catheterized for blood sam-
pling, and the hand was maintained in a hotbox at ~ 55 °C 
to arterialize venous sampling. Baseline samples were 
obtained prior to initiating infusions.
Insulin sensitivity was assayed using a two-step eugly-
cemic clamp technique as described previously [11]. The 
stable isotope [6,6-2H2] glucose (22  μmol/kg prime and 
0.25 μmol/kg/min constant infusion) was infused during 
a 90 min basal period (to allow isotope equilibration) and 
then continued throughout each study. Plasma glucose 
was measured at 5–10 min intervals following the basal 
period. Insulin was initially infused in two stages consist-
ing of rates of 181 and 486 pmol/m2/min, but after ana-
lyzing results from the first 7 patients, the protocol was 
modified to include two stages consisting of insulin infu-
sion rates of 56 and 181 pmol/m2/min in order to avoid 
nearly complete suppression of hepatic glucose produc-
tion at higher insulin infusion rates. Twenty % dextrose 
(containing 1.5% [6,6-2H2] glucose) was infused to main-
tain blood glucose at 5.00 mmol/L for ~ 2 h at each stage. 
Plasma was assayed for 6,6-2H2-glucose enrichment by 
mass spectrometry. Glucose kinetics were determined 
using samples obtained at 10 min intervals during the last 
30 min of the basal period and during each stage of the 
clamp.
Glucose tolerance testing and assays of serum or plasma
Oral glucose tolerance testing was performed by admin-
istering 75  g of glucose followed by sampling at 0, 30, 
60, 90 and 120  min. Samples were assayed for glucose, 
insulin, C peptide, and glucagon. AUC calculations were 
performed using the trapezoid rule for approximating 
integrals. Lipids, lipoproteins, serum chemistries, and 
blood counts were assayed by the Washington University 
Core Laboratory for Clinical Studies, which is CLIA-cer-
tified. Since this project addressed the effects of chloro-
quine on insulin resistance, the cause of which remains 
obscure, the laboratory also performed exploratory 
measurements of putative metabolic mediators that have 
been implicated in insulin resistance and/or its vascular 
complications [12–16]. These included adiponectin, lep-
tin, iron, VEGF (vascular endothelial growth factor), and 
IL-17A. Samples for adiponectin and iron studies were 
assayed at the University of Utah [17].
(See figure on next page.)
Fig. 2 Chloroquine dose escalation trial design and results for hyperinsulinemic‑euglycemic clamping and lipids. a Diagram of the dose escalation 
protocol. A 5–7 week washout period was required between limbs to allow for hematologic recovery following the blood drawing associated with 
clamps. b Glucose disposal rates expressed as μmol glucose/kg body weight/min. Insulin infusion rates were 0, 56, 181, or 486 pmol/m2/min. c 
Hepatic glucose production expressed as (μmol glucose/kg body weight/min) per pmol/L insulin. d Hepatic insulin sensitivity expressed as percent 
suppression of glucose production at 56 pmol/m2/min. e Total, non‑HDL, and LDL cholesterol at the end of each limb. f Triglycerides and HDL 
cholesterol at the end of each limb. Data represent mean ± SE. *P < 0.05 by Tukey’s test for multiple comparisons after repeated measures ANOVA
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Blood pressure determinations
Two techniques were employed: auscultation of seated 
subjects at rest was performed by a trained observer 
who recorded the first and fifth phases of the Korotkoff 
sounds; and, a portable oscillometric device (SpaceLabs 
Medical) recorded results every 20  min during the day 
and every h during the night then data were analyzed as 
mean values over 24 h, between 0800 and 2200 (daytime), 
and between 2200 and 0800 (nighttime).
CIMT assessments
Carotid artery intima-media thickness (CIMT) was 
measured from B-mode images by a single sonogra-
pher using standard approaches [18, 19]. The average of 
3 measurements of the posterior wall of each common 
carotid ~ 1  cm proximal to the carotid bulb was deter-
mined; plaques (wall thickening > 50% of the surrounding 
wall) were excluded. To establish reproducibility, 10% of 
the images were randomly selected and re-measured in 
a blinded fashion by two independent observers. Intra-
observer and inter-observer correlation coefficients were 
0.900 and 0.992.
MRI assessments
A contouring tool on the Philips ViewForum work-
station was used to outline the inner and outer com-
mon carotid artery wall regions (right and left) in the 
first frame immediately below the bifurcation in the 
T2-weighted image, then areas and diameters of the 
vessel wall and lumen were calculated. The maximum 
thickness of the common carotid in the same frame was 
measured with the line tool. Similar measurements were 
made for the internal carotid artery in a slice just beyond 
the bifurcation. For common carotid artery wall con-
trast enhancement, which represents gadolinium leakage 
and late hyper enhancement, pre- and post-injection T1 
Fig. 3 CONSORT statement flow diagram for subjects in the yearlong randomized clinical trial



































eni l es a
B
s ht n o
m
21
Right       Lef t































































































Fig. 4 Yearlong chloroquine trial design and results for carotid imaging. a Diagram of the vascular endpoint trial. After 12 months of placebo 
or chloroquine, both were stopped, then subjects returned at 24 months for limited additional studies. b CIMT results. Standard deviations 
(not included to simplify data presentation) and n values for these data follow. Chloroquine: 0, 0.76625 ± 0.17270 (n = 56); 6 months, 
0.75827 ± 0.17634 (n = 56); 12 months, 0.75769 ± 0.16061 (n = 54); 24 months, 0.77450 ± 0.16540 (n = 53). Placebo: 0, 0.76900 ± 0.11653 (n = 53); 
6 months, 0.76500 ± 0.13087 (n = 51); 12 months, 0.76833 ± 0.11487 (n = 50); 24 months, 0.77280 ± 0.13290 (n = 49). c MRI‑determined contrast 
enhancement. P = 0.0697. d Representative images at baseline and at 12 months for the same vessels. e MRI‑determined common carotid lumen 
area *P = 0.0033. f MRI‑determined common carotid artery diameter. *P = 0.0019. Data represent mean ± SD in c, e, f. Analysis by mixed model 
testing in b, paired t tests in c, e, f 
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weighted images were compared by dividing the artery 
into quadrants. The slice nearest the bifurcation mani-
festing the greatest signal in terms of numbers of quad-
rants enhanced was chosen by visual comparison with 
the same pre-injection slice. If the pre-injection signal 
in the carotid wall appeared bright in any quadrant due 
to signal spatial heterogeneity, and with reference to the 
other arterial wall segments in adjacent or contralateral 
arteries, then the post- injection signal was deemed non-
enhancing. Concurrence of two readers was achieved in 
blinded interpretations.
Monocyte protein preparation, JNK assays, and oxysterol 
determinations
Human monocytes were isolated using a negative selec-
tion technique employing a RosetteSep Human Mono-
cyte Enrichment Cocktail (StemCell Technologies 
#15028), exactly as described by the manufacturer. Cells 
were lysed using a buffer containing 1% Tween 20 and 
0.2% NP40 with protease and phosphatase inhibitors, and 
lysates were aliquoted and stored at − 80 °C.
Total and phospho (Thr183/Tyr185) JNK were assayed 
using chemiluminescent sandwich ELISA kits (Cell Sign-
aling Technologies #7869S and #7849S). Extracts from 
subjects before and 1  year following treatment were 
analyzed in the same assay by an observer masked to 
randomization status. Signals detected from 1  μg lysate 
protein (assayed with BCA reagents from Pierce) were 
determined using a Synergy 4 plate reader and the ratio 
of phospho-JNK to total JNK was calculated. For assays 
of cholestane-3β,5α,6β-triol, plasma samples stored at 
− 80  °C were thawed and combined with BHT (50  μg/
mL). Oxysterols were purified, derivatized, then quan-
tified by GC–MS (m/z 456) in assays performed within 
the linear response range of appropriate standard curves 
[20].
Statistical analyses
Results are expressed as mean ± SD except in Fig.  2 
where results are presented as mean ± SE to simplify 
data presentation. Statistical analyses were performed 
using GraphPad Prism software. For the dose escalation 
study, most data were analyzed using repeated meas-
ures ANOVA with post hoc testing using Tukey’s multi-
ple comparison test for inter-group differences. For the 
yearlong treatment study, most data were analyzed using 
a mixed model approach for repeated measures to allow 
for dealing with missing values. P values for mixed model 
analyses represent an assessment of whether the depend-
ent variable was affected by the randomization group 
(placebo vs. chloroquine) vs. time interaction. Some 
analyses in both trials involving only two groups were 
performed using a two-tailed Student’s t test. Spearman 
correlation coefficients were calculated for the relation-
ships between baseline CIMT in the 116 randomized 
subjects and variables associated with atherosclerosis. 
Two-tailed paired t tests were used to analyze the base-
line vs. 12-month results for MRI imaging and JNK acti-
vation. Binary baseline characteristics and adverse events 
were analyzed using contingency tables and Chi Square 
Test or Fisher’s Exact Test.
Results
Metabolic effects of increasing doses of chloroquine
Characteristics for those completing the dose escalation 
study are shown in Table 1. The primary endpoint of the 
first trial was clamp-determined insulin sensitivity. Two-
stage hyperinsulinemic euglycemic clamps were initially 
performed using insulin at 181 and 486  pmol/m2/min. 
However, data analysis after the first seven patients dem-
onstrated complete suppression of glucose production at 
the higher dose and nearly complete suppression at the 
lower dose, decreasing the ability to detect differences in 
endogenous glucose production in this group of patients 
with metabolic syndrome but not diabetes. Subsequent 
two-stage clamps were performed using insulin infusions 
at 56 and 181 pmol/m2/min. The results from these first 
seven patients are included in Fig.  2b, c; the 486  pmol/
m2/min condition represents data points from these first 
patients for each limb while the 181 pmol/m2/min con-
dition includes data points from these patients in addi-
tion to those from those undergoing clamps at 56 and 
181 pmol/m2/min. There were no differences in glucose 
Table 1 Baseline characteristics of  subjects in  the  dose 
escalation study






 Non‑hispanic white 23
Weight (kg) 101 ± 17
BMI (kg/m2) 35.0 ± 4.4
Waist circumference (cm) 109 ± 13
Fasting glucose (mmol/L) 5.27 ± 0.61
Systolic blood pressure (mmHg) 135 ± 16
Diastolic blood pressure (mmHg) 80 ± 10
Total cholesterol (mmol/L) 5.25 ± 0.67
Non‑HDL cholesterol (mmol/L) 4.11 ± 0.62
LDL cholesterol (mmol/L) 3.23 ± 0.57
Triglycerides (mmol/L) 1.85 ± 0.61
HDL cholesterol (mmol/L) 1.19 ± 0.26
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disposal rates between any of the chloroquine doses as 
shown in Fig. 2b.
There was a dose-dependent effect of chloroquine 
on hepatic glucose production (clamp-determined rate 
of appearance) with significant suppression at doses of 
80  mg/day and 250  mg/day as determined by repeated 
measures ANOVA (Fig. 2c). Figure 2d shows that chloro-
quine increased hepatic insulin sensitivity based on data 
from the 56 pmol/m2/min stage.
There was also an apparent dose-dependent effect of 
chloroquine on fasting levels of total cholesterol, non-
HDL cholesterol, and LDL cholesterol with a significant 
decrease at 250/day as determined by repeated measures 
ANOVA (Fig. 2e). Serum triglycerides and HDL choles-
terol were unchanged (Fig. 2f ).
Chloroquine in this dose escalation study had no 
effect on blood pressure determined using an ambula-
tory monitor as shown in Table 2. SBP, DBP, MAP, and 
magnitude of BP decrease overnight (“dipping” status) 
were unaffected in all limbs. Consistent with an effect 
of chloroquine on hepatic insulin sensitivity, fast-
ing glucose at the time of the clamp was significantly 
decreased (Table 2). Consistent with the lack an effect 
of chloroquine on glucose disposal, OGTT AUC results 
were unaffected in all limbs (Table 2). There was also no 
effect on body weight, glucagon, leptin, NEFA, C-pep-
tide or insulin (Table 2).
There was a trend toward lower levels of TNFα 
(Table  2), but other inflammatory markers includ-
ing CRP and adiponectin were unaffected (Table  2), 
consistent with other large studies of the relationship 
between this adipokine and insulin sensitivity [21].
Iron is linked to the development of diabetes [22] and 
ferritin is the major storage form of iron. Chloroquine 
treatment was associated with a significant decrease in 
ferritin levels in humans (Table 2), confirming an effect 
seen in rodents [23].
Table 2 Dose effect of chloroquine on blood pressure and other variables
Data represent mean ± SD
MAP mean arterial pressure, NEFA non-esterified fatty acids, ND not determined
P values determined by repeated measures ANOVA except for A1c, adiponectin, and iron studies, where P value determined by paired t test
Variable Placebo 80 mg/week 80 mg/day 250 mg/day P value
SBP (mmHg) 121 ± 12 121 ± 10 123 ± 12 123 ± 12 0.5607
DBP (mmHg) 70 ± 7 71 ± 7 73 ± 8 73 ± 9 0.1107
MAP (mmHg) 87 ± 8 88 ± 7 89 ± 9 90 ± 9 0.1944
Overnight MAP dip 8.8 ± 4.2 9.5 ± 5.3 9.5 ± 8.8 9.6 ± 5.0 0.9878
Fasting glucose clamp 5.77 ± 0.53 5.83 ± 0.52 5.83 ± 0.53 5.44 ± 0.65 0.0010*
Fasting glucose OGTT 5.49 ± 0.57 5.77 ± 0.56 5.72 ± 0.62 5.66 ± 0.62 0.0805
OGTT AUC (mmol/L/h) 16.93 ± 3.05 17.65 ± 3.00 17.87 ± 3.22 17.26 ± 3.61 0.3585
Weight (kg) 104 ± 18 103 ± 18 104 ± 19 103 ± 19 0.6041
BMI 35.9 ± 4.3 35.9 ± 4.2 35.9 ± 4.5 35.5 ± 4.6 0.5964
A1c (%) 5.8 ± 0.4 ND ND 5.8 ± 0.4 0.9493
Insulin (pmol/L) 153 ± 94 138 ± 62 166 ± 107 148 ± 80 0.4260
C peptide (nmol/L) 1.16 ± 0.44 1.20 ± 0.38 1.26 ± 0.44 1.25 ± 0.36 0.5473
Glucagon (pg/mL) 110 ± 41 101 ± 26 111 ± 54 102 ± 50 0.3646
Leptin (μg/L) 27.5 ± 11.6 27.2 ± 11.1 31.0 ± 16.4 27.2 ± 11.9 0.2134
NEFA (mmol/L) 0.56 ± 0.15 0.55 ± 0.10 0.58 ± 0.19 0.55 ± 0.16 0.8776
TNFα (pg/mL) 12.9 ± 1.8 13.0 ± 1.7 12.2 ± 1.9 12.4 ± 2.0 0.0890
Fibrinogen (μmol/L) 8.44 ± 1.32 8.38 ± 1.47 8.14 ± 1.09 7.94 ± 1.44 0.3563
IL‑6 (pg/mL) 1.0 ± 1.6 1.4 ± 1.5 1.2 ± 1.6 0.96 ± 1.3 0.4282
Lp(a) (mg/dL) 22.9 ± 17.5 20.9 ± 16.0 22.5 ± 17.2 22.8 ± 18.1 0.1454
CRP (mg/L) 8.3 ± 10.8 7.9 ± 10.6 6.4 ± 7.2 7.5 ± 8.0 0.7455
Adiponectin (μg/mL) 21.6 ± 8.1 ND ND 20.6 ± 5.6 0.3503
Iron (μmol/L) 12.3 ± 4.1 ND ND 11.4 ± 5.5 0.5311
Iron Bind. Cap. (μmol/L) 64.9 ± 8.7 ND ND 65.8 ± 10.0 0.6385
Transferrin (mg/dL) 300.3 ± 47.5 ND ND 303.8 ± 48.5 0.6899
Transferrin Sat. (%) 19.1 ± 6.4 ND ND 17.2 ± 6.9 0.3413
Ferritin (pmol/L) 170 ± 191 ND ND 105 ± 88 0.0155*
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Vascular effects of chloroquine treatment
Baseline characteristics for the 107 subjects who com-
pleted the second trial, a double-blind placebo controlled 
study are shown in Table  3. The primary endpoint of 
the second trial was CIMT. To validate carotid meas-
urements in this study cohort, baseline CIMT values 
for the 116 subjects randomized to chloroquine or pla-
cebo were correlated with common variables associated 
with atherosclerosis. CIMT was positively correlated 
with age  (rs = 0.3963, P < 0.0001), systolic blood pres-
sure  (rs = 0.3379, P = 0.0002), triglycerides  (rs = 0.2936, 
P = 0.0014), cholesterol  (rs = 0.3593, P < 0.0001), and 
LDL-C  (rs = 0.2590, P = 0.0050). There were no correla-
tions with HDL-C, diastolic blood pressure, waist cir-
cumference, BMI, glucose, TNFα, IL-6, VEGF, or IL-17A 
(not shown).
There was no effect of chloroquine on CIMT after 
12  months (Fig.  4b). Because chloroquine has a long 
half-life, imaging was repeated at 24 months, following a 
12-month washout period. These results also showed no 
difference between groups. MRI studies were performed 
only at baseline and at 12 months. Chloroquine did not 
affect contrast enhancement, a pre-specified secondary 
endpoint of the study (Fig.  4c, P = 0.0697, paired two-
tailed t test). Representative images of vessels at baseline 
and 12 months are shown in Fig. 4d. Carotid dimensions 
were also assessed by MRI. Chloroquine was associated 
with a decrease in common carotid artery luminal area 
(Fig. 4e, P = 0.0033) and diameter (Fig. 4f, P = 0.0019).
Effects of chloroquine on blood pressure, lipids, and other 
variables
Drug treatment over the first year was associated with a 
significantly lower diastolic blood pressure (P = 0.0252 
at 12 months), results that were driven by a 4.9 mm Hg 
decrease at the 6 month time point (Fig. 5a). Ambulatory 
monitoring results (performed at baseline, 6  months, 
and 12  months but not at 24  months) were consistent 
with a beneficial effect of chloroquine on blood pres-
sure. Drug treatment over the first year was associated 
with significantly lower daytime mean arterial pressure 
(Fig. 5b, P = 0.0484). Daytime (P = 0.0804) and nighttime 
(P = 0.0659) systolic pressures by ambulatory monitor-
ing were not different (Fig. 5c, d). By mixed model test-
ing for the interaction between group and time, there 
was no effect of chronic chloroquine on lipids. How-
ever, at 12  months, a pre-specified secondary endpoint, 
total cholesterol was 9% lower (Fig.  5e, P = 0.0089 by 
unpaired t test), non-HDL cholesterol was 12% lower 
(Fig.  5f, P = 0.0048 by unpaired t test), and LDL-C was 
13% lower (Fig. 5g, P = 0.0038 by unpaired t test) in the 
chloroquine group. Glucose area under the curve (AUC) 
as well as HOMA-IR and the Matsuda index, measures of 
insulin sensitivity [24], were not different between groups 
(Table 4). There was no effect of chloroquine on insulin 
AUC, C peptide AUC, or the insulinogenic index (the 
difference between insulin at 30 min and 0 min divided 
by the difference between glucose at 30 min and 0 min) 
(Table 4), suggesting that chronic chloroquine treatment 
at this dose does not impact insulin levels in humans. 
Glucagon AUC, creatinine, ALT, and hematologic vari-
ables were not different between treatment groups 
(Table 4).
Potential mechanistic mediators
JNK is a stress kinase implicated in obesity-associated 
chronic inflammation [25]. JNK activation in monocytes, 
a pre-specified secondary endpoint, was significantly 
decreased in chloroquine-treated but not placebo-treated 
subjects (Fig.  6a). Reactive oxygen species activate JNK 
and have been implicated in the pathophysiology of 
obesity-associated conditions [26]. Plasma cholesterol 
oxidation products are elevated in diabetes and coro-
nary artery disease [20]. Cholestane-3β, 5α, 6β-triol, 
one species that may reflect clinically relevant oxidative 
Table 3 Baseline characteristics of subjects in the double-
blind study
Data represent mean ± SD
Variable Chloroquine group Placebo group P value
Gender (F/M) 44/12 33/18 0.1108
Age 55 ± 12 55 ± 9 0.9999
Race (AA/NHW/H/NA) 9/45/1/1 6/45/0/0 0.4990
Smoking status
 Current 8 10 0.4341
 Past 21 23 0.2962




Fish oil treatment 5 10 0.1632
Waist circumference 110.4 ± 10.5 108.9 ± 11.8 0.6538
BMI 36.2 ± 5.0 34.2 ± 5.0 0.0433*
SBP
 Screen 137.1 ± 14.3 140.2 ± 13.2 0.2385
 Randomization 129.2 ± 11.4 134.0 ± 10.1 0.0237*
DBP
 Screen 82.8 ± 9.5 83.0 ± 9.7 0.9483
 Randomization 78.3 ± 7.4 79.7 ± 7.2 0.3244
Glucose 5.48 ± 0.53 5.52 ± 0.64 0.6960
Triglycerides 1.84 ± 1.04 1.82 ± 0.93 0.9155
HDL‑C 1.14 ± 0.26 1.14 ± 0.27 0.9603
Cholesterol 5.00 ± 0.85 5.18 ± 1.15 0.3834
LDL‑C 3.04 ± 0.68 3.28 ± 0.82 0.1073
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stress [20], was significantly decreased in the chloroquine 
group at 12 months (Fig. 6b).
Adverse events
For the dose escalation study, there were no serious 
adverse events (Table 5). Not unexpectedly given the rig-
ors of a series of clamps, there were several study-related 
events. Of adverse events that were not directly study-
related, infections were the most common.
For the double blind study, there were 7 serious events. 
In the placebo group, one subject presented with a new 
diagnosis of prostate cancer. One subject underwent a 
right knee replacement. In the chloroquine group, one 
patient developed transverse myelitis presenting with 
left leg weakness that subsequently improved but did 
not completely resolve. One subject underwent carotid 
endarterectomy for asymptomatic near-total carotid 
occlusion detected at 6  months. One subject was hos-
pitalized for a cutaneous staphylococcus infection that 
resolved with appropriate therapy. One subject was 
treated for acute appendicitis, stopped the study medica-
tion for 1 week then resumed without incident. One sub-
ject was found to have a positive PPD without evidence 
of pulmonary tuberculosis.
Total adverse events were similar between groups 
(Table  6). There were more infectious events in those 























































































































































































Fig. 5 Blood pressure and lipid responses in the yearlong chloroquine trial. a Diastolic blood pressure over 24 months determined by conventional 
testing. b–d Blood pressures over 12 months, determined by an ambulatory monitoring device. e–i Lipids and lipoproteins over 24 months. P 
values were determined by mixed model treatment of repeated measures
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randomized to chloroquine but this was not signifi-
cant (51 vs. 42, P = 0.0609). No subject in either study 
developed retinal pigmentary changes that may occur 
with chloroquine. For the double blind study, observers 
masked to the treatment assignment examined each sub-
ject at 0, 6, 12, and 24  months. Ocular adverse events 
were not significantly different between treatment groups 
(Table 6).
Table 4 Effects of chloroquine vs. placebo over 24 months (off either, i.e. washout, months 12–24)
Data represent mean ± SD
P values determined by mixed model approach to repeated measures except where indicated
Variable Baseline 6 months 12 months 24 months P value
Waist (cm)
 Chloroquine 110.4 ± 10.5 112.5 ± 12.6 112.6 ± 13.6 113.2 ± 16.6 0.5578 (12 m)
 Placebo 108.9 ± 11.8 110.4 ± 13.8 109.8 ± 12.4 108.9 ± 15.9
Weight (kg)
 Chloroquine 102.9 ± 16.7 102.9 ± 16.7 103.1 ± 19.2 105.9 ± 20.4 0.1323
 Placebo 99.7 ± 18.5 98.7 ± 18.5 99.2 ± 17.8 100.5 ± 21.2 0.1909 (t test 24 m)
Fasting glucose
 Chloroquine 5.48 ± 0.53 5.36 ± 0.55 5.30 ± 0.51 5.58 ± 0.73 0.2741 (12 m)
 Placebo 5.52 ± 0.64 5.52 ± 0.62 5.51 ± 0.71 5.63 ± 0.74 0.0930 (t test 12 m)
Glucose AUC 
 Chloroquine 16.32 ± 2.46 15.94 ± 2.24 16.17 ± 2.58 16.97 ± 3.20 0.2537
 Placebo 16.54 ± 3.49 16.87 ± 3.29 16.43 ± 3.34 17.50 ± 3.85
Insulin AUC 
 Chloroquine 1202 ± 681 1118 ± 542 1143 ± 603 1213 ± 716 0.2479
 Placebo 1003 ± 524 1054 ± 588 995 ± 570 1022 ± 613
C peptide AUC 
 Chloroquine 7.46 ± 2.33 7.23 ± 2.10 7.16 ± 2.20 7.39 ± 2.43 0.2918
 Placebo 6.49 ± 1.80 6.69 ± 2.06 6.46 ± 2.00 6.79 ± 2.06
HOMA‑IR
 Chloroquine 3.89 ± 2.23 3.85 ± 2.21 3.57 ± 2.12 3.72 ± 3.53 0.8421
 Placebo 3.54 ± 2.03 3.64 ± 2.08 3.30 ± 2.23 3.29 ± 2.26
Matsuda index
 Chloroquine 2.89 ± 1.72 2.88 ± 1.55 3.13 ± 2.31 3.43 ± 2.84 0.8997
 Placebo 3.21 ± 1.89 3.07 ± 1.64 3.50 ± 2.14 3.56 ± 2.70
Insulinogenic index
 Chloroquine 1.40 ± 1.75 1.17 ± 0.87 1.24 ± 0.87 1.12 ± 0.89 0.4988
 Placebo 1.05 ± 0.77 1.03 ± 0.67 1.09 ± 0.88 1.13 ± 1.62
Glucagon AUC 
 Chloroquine 174.0 ± 63.5 152.3 ± 60.3 126.8 ± 43.3 ND 0.6126
 Placebo 168.0 ± 60.6 138.7 ± 46.7 119.8 ± 36.2 ND
Creatinine (μmol/L)
 Chloroquine 68 ± 14 67 ± 15 66 ± 15 ND 0.7859
 Placebo 66 ± 16 65 ± 17 65 ± 17
ALT
 Chloroquine 26 ± 16 26 ± 19 26 ± 15 ND 0.2056
 Placebo 25 ± 12 27 ± 16 23 ± 9 ND
WBC count
 Chloroquine 6.7 ± 1.8 6.3 ± 1.6 6.0 ± 1.5 ND 0.7249
 Placebo 6.5 ± 1.7 6.3 ± 1.8 6.1 ± 1.9 ND
Hemoglobin
 Chloroquine 13.6 ± 1.1 13.3 ± 1.1 13.2 ± 1.2 ND 0.8953
 Placebo 13.8 ± 0.8 13.5 ± 0.9 13.5 ± 0.9 ND
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Discussion
We tested the hypothesis that the anti-malarial drug 
chloroquine, which activates the kinase ATM, improves 
insulin sensitivity and decreases atherosclerosis in 
humans with metabolic syndrome. In mice, low dose 
chloroquine improves insulin sensitivity, decreases 
atherosclerosis, and suppresses activation of JNK in mac-
rophages through pathways that require the presence of 
ATM [6]. The absence of ATM in mice affects hepatic 
insulin sensitivity and promotes atherosclerosis, suggest-
ing the involvement of processes that link hepatic insulin 
resistance and vascular disease. Accordingly, we trans-
lated these findings to humans by conducting two trials, 
the first to determine if chloroquine improves insulin 
sensitivity in the liver, and the second to determine if 
chloroquine decreases CIMT.
The overall results were disappointing. Hyperinsu-
linemic euglycemic clamp studies demonstrated a dose 
response relationship between chloroquine administra-
tion and hepatic insulin sensitization but the effect was 
modest. Treatment with chloroquine for 1 year (using the 
lowest dose found to increase hepatic insulin sensitivity) 
had no effect on the primary endpoint of CIMT and no 
beneficial effects on MRI imaging. One limitation of the 
study is that it may have been underpowered to detect a 
difference in CIMT. Sample size estimates at the time of 
initiation of these studies were based on reports show-
ing that insulin sensitizers had effects on CIMT with 
groups of 31–57 subjects [27–30], but subsequent work 
indicated the need for larger sample sizes [31]. Taken 
together, our findings suggest that chloroquine will 
not be clinically useful for the treatment of metabolic 
syndrome.
There were positive results from our studies. Chronic 
administration of chloroquine lowered blood pressure, 
decreased activation of JNK in circulating monocytes, 
and decreased concentration of a cholesterol oxidation 
product that reflects oxidative stress. These findings 
suggest that chloroquine decreases systemic inflamma-



















































Fig. 6 Effects of placebo and chloroquine on potential mechanistic mediators. a Activated JNK in circulating monocytes at baseline and 12 months. 
*P = 0.0164; P = 0.3343 for placebo; paired t tests. b Plasma concentrations of the oxysterol cholestane‑3β, 5α, 6β‑triol at 12 months. *P = 0.0031; 
unpaired t test
Table 5 Adverse events in the dose escalation study
Parentheses denote %
Adverse event Subjects (%)
Total subjects with any event 24 (69)
Subjects with a serious adverse event 0 (0)
Total adverse events 57 (100)
Study related 14 (25)
 IV placement difficulties 1 (1.8)
 IV infiltration 1 (1.8)
 Phlebitis 1 (1.8)
 Skin reaction to tape 1 (1.8)
 Extremity erythema due to BP cuff 1 (1.8)
 Vasovagal episode with IV placement 1 (1.8)
 Incorrect stable isotope administered 1 (1.8)
 Nausea 3 (5)
 Anemia 4 (7)
Not study related 43 (75)
 Infectious 15 (26)
 Allergy/immunology 3 (5)
 Musculoskeletal 8 (14)
 CNS 3 (5)
 Psychiatric 5 (9)
 Cardiovascular 2 (4)
 GI 4 (7)
 Metabolic 3 (5)
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syndrome. The inhibition of JNK is known to enhance 
insulin sensitivity and decrease atherosclerosis in ani-
mals [32, 33]. Oxidative stress activates JNK, and recent 
studies implicate ATM, which is activated by chloro-
quine, in modulation of reactive oxygen species gen-
eration [34]. Metformin, the most widely used insulin 
sensitizer, appears to work through redox-dependent 
mechanisms in liver [35]. Variants in the ATM gene 
alter the glycemic response to metformin in humans 
[36]. These findings raise the possibility that chloro-
quine induction of ATM activity modifies redox signal-
ing to decrease insulin resistance, but in humans these 
effects are small.
Hydroxychloroquine, closely related to chloroquine, 
improves glycemic control in poorly controlled type 2 
diabetes in humans [37] and may improve glucose metab-
olism in human prediabetes [38]. Its use in rheumatoid 
arthritis is associated with a reduced risk for develop-
ing diabetes in large observational studies [39, 40], and 
its administration to healthy obese subjects without the 
metabolic syndrome increases the Matsuda index of 
insulin sensitivity [41].
Chloroquine was well tolerated. Subjects in the 
dose escalation study received 7.2  g and those in the 
yearlong study 29.2 g. Retinopathy is a serious but rare 
adverse effect of chloroquine; our subjects had regular 
eye exams and retinopathy was not detected.
Conclusions
Low dose chloroquine modestly enhanced hepatic insu-
lin sensitivity but did not affect CIMT. Despite some 
positive effects on secondary endpoints including the 
demonstration of suppression of the stress kinase JNK, 
overall results suggest that chloroquine will not be use-
ful for the treatment of metabolic syndrome in humans.
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Table 6 Adverse events in the double-blind study
Parentheses denote %
P values determined using contingency tables
Adverse event Chloroquine subjects (%) Placebo subjects (%) P value
Total subjects with any event 44 (76) 39 (67) 0.4107
Subjects with a serious adverse event 5 (9) 2 (3) 0.4385
Total adverse events 109 (100) 105 (100) –
Infectious 51 (47) 42 (40) 0.0609
Allergy/immunology 5 (5) 10 (10) 0.2681
Musculoskeletal 17 (16) 15 (15) 0.8357
CNS 5 (5) 3 (3) –
Psychiatric 5 (5) 6 (6) –
Hematologic/neoplasm 2 (2) 2 (2) –
Cardiovascular 2 (2) 3 (3) –
GI 3 (3) 3 (3) –
GU 2 (2) 2 (2) –
Metabolic 1 (1) 6 (6) –
Miscellaneous 0 (0) 3 (3) –
Ocular 16 (15) 10 (10) 0.2654
Ocular details
 Retinal 3 3 –
 Lens 4 2 –
 Vision 2 0 –
 Infectious 2 0 –
 Glaucoma 2 2 –
Page 15 of 16McGill et al. Diabetol Metab Syndr           (2019) 11:61 
Acknowledgements
We appreciate the efforts of the dedicated volunteers who devoted consider‑
able time to participate in these trials, and the suggestions of the members of 
the data safety and monitoring board.
Authors’ contributions
CFS obtained the funding; JBM, MJ, SH, WTC and CFS conducted the clinical 
trial; WTC, KEY, REO, BR, MBK, DAM, DSO and CFS analyzed samples; LLF and 
VGD conducted the CIMT studies; SAW conducted the MRI studies, CFS and 
KBS analyzed the data. CFS wrote the manuscript; JBM edited the manuscript. 
All authors read and approved the final manuscript.
Funding
This work was supported by NIH Grants HL083762, DK020579, DK076729, 
DK056341, GM103422, UL1RR024992, KL2RR024994.
Availability of data and materials
The datasets used and analyzed in the current study are available from the 
corresponding authors on reasonable request. All data generated during this 
study are included in this published article.
Ethics approval and consent to participate
Ethics approval was granted by the Washington University Human Research 
Protection Office, Washington University in St. Louis, St. Louis, Missouri. All 




The authors declare that they have no competing interests.
Author details
1 Division of Endocrinology, Metabolism & Lipid Research, Department 
of Medicine, Washington University School of Medicine, 660 South Euclid 
Avenue, Box 8127, St. Louis, MO 63110, USA. 2 Program in Physical Therapy, 
Washington University, St. Louis, MO, USA. 3 Division of Biostatistics, Washing‑
ton University, St. Louis, MO, USA. 4 Cardiovascular Division, Washington Uni‑
versity, St. Louis, MO, USA. 5 Department of Pharmacology & Cancer Biology, 
Duke University, Durham, NC, USA. 6 Department of Internal Medicine, Wake 
Forest School of Medicine, Winston‑Salem, NC, USA. 7 Department of Cell Biol‑
ogy & Physiology, Washington University, St. Louis, MO, USA. 
Received: 5 April 2019   Accepted: 20 July 2019
References
 1. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. 
Lancet. 2010;375(9710):181–3.
 2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The 
metabolic syndrome and cardiovascular risk a systematic review and 
meta‑analysis. JACC. 2010;56(14):1113–32.
 3. Solinas G, Becattini B. JNK at the crossroad of obesity, insulin resistance, 
and cell stress response. Mol Metab. 2017;6(2):174–84.
 4. Look ARG, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, 
et al. Association of the magnitude of weight loss and changes in 
physical fitness with long‑term cardiovascular disease outcomes in 
overweight or obese people with type 2 diabetes: a post hoc analysis of 
the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 
2016;4(11):913–21.
 5. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 
2006;116(7):1813–22.
 6. Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, et al. 
ATM‑dependent suppression of stress signaling reduces vascular disease 
in metabolic syndrome. Cell Metab. 2006;4(5):377–89.
 7. Mercer JR, Cheng KK, Figg N, Gorenne I, Mahmoudi M, Griffin J, et al. 
DNA damage links mitochondrial dysfunction to atherosclerosis and the 
metabolic syndrome. Circ Res. 2010;107(8):1021–31.
 8. Le Guezennec X, Brichkina A, Huang YF, Kostromina E, Han W, Bulavin DV. 
Wip1‑dependent regulation of autophagy, obesity, and atherosclerosis. 
Cell Metab. 2012;16(1):68–80.
 9. Razani B, Feng C, Semenkovich CF. p53 is required for chloroquine‑
induced atheroprotection but not insulin sensitization. J Lipid Res. 
2010;51(7):1738–46.
 10. Geisel MH, Bauer M, Hennig F, Hoffmann B, Lehmann N, Mohlenkamp 
S, et al. Comparison of coronary artery calcification, carotid intima‑
media thickness and ankle‑brachial index for predicting 10‑year 
incident cardiovascular events in the general population. Eur Heart J. 
2017;38(23):1815–22.
 11. Subramanian S, DeRosa MA, Bernal‑Mizrachi C, Laffely N, Cade WT, Yar‑
asheski KE, et al. PPARalpha activation elevates blood pressure and does 
not correct glucocorticoid‑induced insulin resistance in humans. Am J 
Physiol Endocrinol Metab. 2006;291(6):E1365–71.
 12. Derosa G, Fogari E, D’Angelo A, Bianchi L, Bonaventura A, Romano D, et al. 
Adipocytokine levels in obese and non‑obese subjects: an observational 
study. Inflammation. 2013;36(4):914–20.
 13. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, et al. Effects of 
Berberis aristata/Silybum marianum association on metabolic parameters 
and adipocytokines in overweight dyslipidemic patients. J Biol Regul 
Homeost Agents. 2013;27(3):717–28.
 14. Azimi‑Nezhad M, Mirhafez SR, Stathopoulou MG, Murray H, Ndiaye NC, 
Bahrami A, et al. The relationship between vascular endothelial growth 
factor cis‑ and trans‑acting genetic variants and metabolic syndrome. Am 
J Med Sci. 2018;355(6):559–65.
 15. Suarez‑Ortegon MF, Blanco E, McLachlan S, Fernandez‑Real JM, 
Burrows R, Wild SH, et al. Ferritin levels throughout childhood and 
metabolic syndrome in adolescent stage. Nutr Metab Cardiovasc Dis. 
2019;29(3):268–78.
 16. Demir E, Harmankaya NO, Kirac Utku I, Aciksari G, Uygun T, Ozkan H, 
et al. The relationship between epicardial adipose tissue thickness and 
serum interleukin‑17a level in patients with isolated metabolic syndrome. 
Biomolecules. 2019;9(3):97.
 17. Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, et al. 
Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 
2012;122(10):3529–40.
 18. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of 
carotid ultrasound to identify subclinical vascular disease and evaluate 
cardiovascular disease risk: a consensus statement from the American 
Society of Echocardiography Carotid Intima‑Media Thickness Task Force. J 
Am Soc Echocardiography. 2008;21(2):93–111.
 19. de Fuentes L, Waggoner AD, Mohammed BS, Stein RI, Miller BV 3rd, Foster 
GD, et al. Effect of moderate diet‑induced weight loss and weight regain 
on cardiovascular structure and function. JACC. 2009;54(25):2376–81.
 20. Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, Gale SE, et al. 
Cholesterol oxidation products are sensitive and specific blood‑based 
biomarkers for Niemann‑Pick C1 disease. Sci Transl Med. 2010;2(56):5681.
 21. Yaghootkar H, Lamina C, Scott RA, Dastani Z, Hivert MF, Warren LL, 
et al. Mendelian randomization studies do not support a causal role for 
reduced circulating adiponectin levels in insulin resistance and type 2 
diabetes. Diabetes. 2013;62(10):3589–98.
 22. Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 
2013;17(3):329–41.
 23. Ramm GA, Powell LW, Halliday JW. Pathways of intracellular trafficking 
and release of ferritin by the liver in vivo: the effect of chloroquine and 
cytochalasin D. Hepatology. 1994;19(2):504–13.
 24. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral 
glucose tolerance testing: comparison with the euglycemic insulin 
clamp. Diabetes Care. 1999;22(9):1462–70.
 25. Han MS, Jung DY, Morel C, Lakhani SA, Kim JK, Flavell RA, et al. JNK expres‑
sion by macrophages promotes obesity‑induced insulin resistance and 
inflammation. Science. 2013;339(6116):218–22.
 26. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal 
role in multiple forms of insulin resistance. Nature. 2006;440(7086):944–8.
 27. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent 
inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 
diabetes. J Clin Endocrinol Metab. 1998;83(5):1818–20.
 28. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura 
Y. Rapid communication: inhibitory effect of pioglitazone on carotid 
Page 16 of 16McGill et al. Diabetol Metab Syndr           (2019) 11:61 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 
2001;86(7):3452–6.
 29. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized 
trial of the effects of rosiglitazone and metformin on inflammation and 
subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 
2007;153(3):445.
 30. Xiang AH, Hodis HN, Kawakubo M, Peters RK, Kjos SL, Marroquin A, et al. 
Effect of pioglitazone on progression of subclinical atherosclerosis in 
non‑diabetic premenopausal Hispanic women with prior gestational 
diabetes. Atherosclerosis. 2008;199(1):207–14.
 31. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji 
M, et al. Pioglitazone slows progression of atherosclerosis in predia‑
betes independent of changes in cardiovascular risk factors. ATVB. 
2013;33(2):393–9.
 32. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa 
M, et al. Possible novel therapy for diabetes with cell‑permeable JNK‑
inhibitory peptide. Nat Med. 2004;10(10):1128–32.
 33. Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, Akhmedov A, et al. 
Requirement of JNK2 for scavenger receptor A‑mediated foam cell 
formation in atherogenesis. Science. 2004;306(5701):1558–61.
 34. Valentin‑Vega YA, Maclean KH, Tait‑Mulder J, Milasta S, Steeves M, Dorsey 
FC, et al. Mitochondrial dysfunction in ataxia‑telangiectasia. Blood. 
2012;119(6):1490–500.
 35. Madiraju AK, Qiu Y, Perry RJ, Rahimi Y, Zhang XM, Zhang D, et al. Met‑
formin inhibits gluconeogenesis via a redox‑dependent mechanism 
in vivo. Nature Med. 2018;24(9):1384–94.
 36. GoDarts, Group UDPS, Wellcome Trust Case Control C, Zhou K, Bel‑
lenguez C, Spencer CC, et al. Common variants near ATM are associated 
with glycemic response to metformin in type 2 diabetes. Nat Genetics. 
2011;43(2):117–20.
 37. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of 
hydroxychloroquine in patients with type 2 diabetes mellitus who are 
refractory to sulfonylureas–a randomized trial. Diabetes Res Clin Prac. 
2002;55(3):209–19.
 38. Sheikhbahaie F, Amini M, Gharipour M, Aminoroaya A, Taheri N. The effect 
of hydroxychloroquine on glucose control and insulin resistance in the 
prediabetes condition. Adv Biomed Res. 2016;5:145.
 39. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. 
Hydroxychloroquine and risk of diabetes in patients with rheumatoid 
arthritis. JAMA. 2007;298(2):187–93.
 40. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. 
Association between disease‑modifying antirheumatic drugs and 
diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 
2011;305(24):2525–31.
 41. Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH. Hydroxy‑
chloroquine improves insulin sensitivity in obese non‑diabetic individu‑
als. Arthritis Res Ther. 2012;14(3):R135.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
